Review Article
Molecular Diagnosis of Sexually Transmitted Chlamydia trachomatis in the United States
Table 2
Performance characteristics of three commercially-available Chlamydia trachomatis molecular screening platforms per manufacturer-provided data. Ranges reflect differences in performance characteristics between specimens collected from symptomatic and asymptomatic individuals (when specified).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
†APTIMA Combo 2 clinician-collected vaginal swab sensitivity range 96.5–96.7%, specificity range 96.4–97.2%; APTIMA Combo 2 patient-collected vaginal swab sensitivity 98.4%, specificity 96.8%. |